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Abstract: Pathologies of the genito-urinary tract are responsible for a considerable disease burden
worldwide, leading to significant losses of income, lost working days, increased expenditures
for national healthcare systems, and decreased quality of life (QoL) in the affected patients. Among
these diseases, infections and malignancies in this anatomical region are some of the most important
illnesses in human medicine; nevertheless, benign prostate hyperplasia (BPH), erectile dysfunction,
hypospadias, urinary incontinence, and vesicoureteral reflux are also relevant disorders affecting
millions. The publication of various microbiological and clinical studies in urology from different
geographical regions has important ramifications from the standpoint of epidemiology: on one
hand, reported data may influence the development of therapeutic guidelines for urinary tract
infections (UTIs) (empiric antibiotic-therapy) and malignancies (including classical cytotoxic drug
protocols and next-generation anticancer therapies) both locally and internationally; on the other hand,
the relevant stakeholders and government representatives often base their decisions on published
evidence. Therefore, novel studies in the field of urology are strongly encouraged to maintain and
improve the high standard of patient care internationally and to ensure continuous information
supply for international datasets on the causative agents of UTIs and cancer registries. The present
Editorial aims to highlight some relevant studies published from the field of urology in Medicina over
the last several years.
Keywords: urology; renal; epidemiology; urinary tract infections; urological cancers; malignancies;
erectile dysfunction; antibiotics
Pathologies of the genito-urinary tract are responsible for a considerable disease burden worldwide,
leading to significant losses of income, lost working days, increased expenditures for national
healthcare systems, and decreased quality of life (QoL) in the affected patients [1]. Among these
diseases, infections and malignancies in this anatomical region are some of the most important
illnesses in human medicine; nevertheless, benign prostate hyperplasia (BPH), erectile dysfunction,
hypospadias, urinary incontinence, and vesicoureteral reflux are also relevant disorders affecting
millions [2]. Before the 2000s, systematic data collection on the epidemiology of urological ailments was
lacking. In 2001, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) initiated
the Urologic Diseases in America (UDA), with the aim of quantifying the importance and the burden
of urological diseases in the United States, in both medical and financial terms [3]. After the success
of the initial project (which was a significant undertaking), the project was renewed in 2007 to further
deepen the understanding of the epidemiology and costs of urinary diseases in America. At present,
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the Global Burden of Disease (GBD) Study provides the most comprehensive data on the disease
burden associated with the pathologies of the urinary tract [4].
Urinary tract infections (UTIs; see Table 1) are the third most common types of infections
worldwide (following infections of the respiratory tract and the gastrointestinal tract), affecting
both outpatients (community-acquired UTIs; CA-UTI) and inpatients (hospital-acquired UTIs; HA-UTI)
to a considerable degree [5,6]. As a matter of fact, HA-UTIs account for 25–50% of nosocomial infections
overall, representing a serious economic and public health issue for healthcare institutions [7].
UTIs are a common reason for visiting physicians and for the prescription of antibiotics, therefore
their inappropriate diagnosis may lead to excess consumption of antimicrobial drugs [8,9]. The diagnosis
of UTIs is usually based on the clinical presentation and symptoms of the patient, in addition to positive
urine analysis result or culture [9]. UTIs should be differentiated as uncomplicated and complicated
UTIs, as this classification has important ramifications in therapy; the risk of treatment failure
and sequelae is more common in complicated infections [5–10]. In essence, all non-uncomplicated
UTIs should be considered as complicated infections. During the diagnosis of UTIs, patient factors
should also be considered, which may modify the risk of developing these diseases or may affect
decision-making processes in diagnostic and therapeutic choices [7–11]. These host factors include
underlying conditions, such as the presence of diabetes, immunosuppression or transplantation, spinal
cord injuries, malignancies, pregnancy, and the advanced age of the patients. The most common
etiological agents in UTIs are well-known; however, there is significant spatio-temporal variation
in the distribution of these pathogens and their antibiotic-susceptibility patters [9,12].
Table 1. Different types of urinary tract infections.
Asymptomatic bacteriuria
Uncomplicated UTI/cystitis
Recurrent UTIs
Acute/chronic pyelonephritis
Catheter-associated UTIs
Prostatitis
Urosepsis
As a part of local antimicrobial stewardship-initiatives, Gajdács et al. have aimed to comprehensively
characterize the causative agents of CA-UTIs and HA-UTIs in a 1820-bed teaching hospital
in Hungary that is responsible for serving tertiary-care for many of the patients in Southern
Hungary. At first, the authors have published their results regarding the prevalence and
the resistance rates of uropathogenic E. coli and Klebsiella spp. over a decade-long study period,
with an emphasis on the treatment options of extended-spectrum β-lactamase (ESBL)-producing
isolates [13–15]. E. coli isolates were also characterized based on their ability to ferment lactose
(to lac+ and lac- isolates, respectively), which is an important biochemical marker of this species [16].
Subsequently, the authors have also assessed the relevance of other Gram-negative bacteria in the same
time-frame (2008–2017), i.e., Citrobacter-Enterobacter-Serratia species [17], members of the Proteae
tribe (Proteus-Providencia-Morganella) [18], and non-fermenting Gram-negative bacteria, as urinary
pathogens [19]. With the data collected on resistance rates, Gajdács et al. have performed a secondary
analysis of the resistance rates of Gram-negative urinary pathogens, using classical and novel,
clinically relevant resistance indicators (usual drug resistance (UDR); difficult-to-treat resistance (DTR);
and modified version of DTR (mDTR/mcDTR)) specific to UTIs [20]. Pursuing data to have a complete
epidemiological snapshot of the 10-year period, the authors have also reported on the epidemiology
of Gram-positive cocci (i.e., staphylococci, streptococci, and enterococci [21]) and Candida species
as possible pathogens in UTIs [22]. Urine obtained by suprapubic bladder aspiration is an invasive
sampling methodology, which allows for sampling without the risk of contamination, and it also
allows for the anaerobic processing of the samples. During the analysis of suprapubic urine samples
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in the respective 10-year period, the authors have also found some anaerobic pathogens (namely,
Finegoldia magna, Peptococcus niger, and Peptinophilus indolicus) in upper UTIs [23].
Biofilm-formation is an important factor in the initiation and the pathogenesis of catheter-associated
UTIs; additionally, biofilms provide protection for these bacteria against the immune cells of the body
and the diffusion of antibiotics [9,12]. Behzadi et al. assessed the possible correlation between
the production of n = 250 mucoid-variant colonies, biofilm-positivity, and the antibiotic-resistant
phenotype in uropathogenic E. coli isolates [24]. During laboratory assays, 62.0% of isolates produced
mucoid colonies and 47.6% of the tested isolates produced biofilm. While there was no association
found between biofilm-positivity and resistance to ciprofloxacin, trimethoprim/sulfamethoxazole, and
fosfomycin, biofilm-producers were significantly less common among ESBL-positive isolates [24].
The results of this study have been further verified by the findings of Whelan et al. [25]. Prakapaite et al.
studied n = 100 uropathogenic E. coli isolates recovered from uretheral scrapings using phenotypic
methods and phylogenetic analyses using multiplex polymerase chain reaction (PCR); they have found
elevated resistance-levels to cephalosporins and fluoroquinolones in the UTI-associated serogroups
(O15, O22 and O25, respectively), indicating that the use of these drugs as first-line antimicrobials should
be re-considered and alternative drugs should be administered in UTIs [26]. Mickymaray and Al Aboody
performed an in vitro study to ascertain the antibacterial and anti-oxidant properties of fifteen different
spices against relevant uropathogenic bacteria. Out of the tested spices, Acorus calamus, Alpinia galangal,
Armoracia rusticana, Capparis spinosa, and Aframomum melegueta had potent anti-oxidant activities
(measured by 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,20-azinobis-(3-ethylbenzothiazoline-6-sulfonic
acid (ABTS) and the total reducing power (TRP) assays), while A. calamus, A. melegueta, and C. spinosa
were the most effective as antimicrobials, with potent inhibitory activities against K. aerogenes, P. mirabilis,
and S. aureus. They have highlighted that the use of these spices as complementary medicine in UTIs may
be worthy of consideration [27]. Kazlauskas et al. determined the value of diuretic ultrasonography
in the diagnosis of obstructive hydronephrosis in a cohort of 72 patients (in the study population,
hydronephrosis was more commonly unilateral [84.7%, n = 61]); as a result of their study, the authors
have concluded that diuretic ultrasonography used as an adjunctive investigation method may
aid in the prediction of obstructive hydronephrosis [28].
Dženkevičiūtė et al. assessed the association of erectile dysfunction (ED) and asymptomatic
cardiovascular illness in Lithuania in a case-control study: carotid intima media thickness and left
ventricular mass index were found to be significantly higher in the ED-group, while no differences
were seen regarding pulse wave velocity, atherosclerotic plaque count, and other laboratory tests [29].
Their study has concluded that ED (which was associated with a left ventricular mass index) may
be a marker of early cardiovascular illness [29]. In the study by Stolic et al., the survival of patients
on hemodialysis with ED (an independent risk factor for mortality) was assessed: from the cohort
of 70 patients, 60% (n = 42) died during the study period (mean age: 57 ± 6.8 years). Overall, their
study highlighted that preserved diuresis, lower severity of cardiovascular illness, less-thick intima
media in the carotid arteries, and high-quality hemodialysis were all associated with improved survival
in patients with hemodialysis [30]. Bener et al. compared the prevalence of ED among men with
normal blood pressure and men with hypertension in Qatar, using the International Index of Erectile
Function (IIEF) as a scale of sexual dysfunction: among n = 296 patients with hypertension, 66.2%
had ED, while this ratio was much lower among normotensive patients (p < 0.001); additionally, age,
highest level of education, presence of T2DM, and current occupation all had significant influence
on the level of sexual dysfunction [31].
Urologic cancers affect the organs and anatomical structures of the male and female urinary system
and the male reproductive organs (see Table 2). The incidence of all urologic cancers is increasing
due to the increase in the life expectancy of the population globally [32]. Bladder cancer (where
abnormal cell growth is detected in the lining of the urinary bladder) has the highest incidence among
urologic malignancies (incidence—360,000, mortality—150,000), while prostate cancer is the second
most prevalent male cancer worldwide [32,33]. Bladder cancer is three-to-four times more common
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in males than in females, usually in patients over 70 years of age [33]. Many of the prostate cancers show
slow growth; they do not metastasize, and they do not reduce the quality of life of the affected patients.
On the other hand, renal cancers (i.e., renal cell carcinomas; RCC) have the highest mortality rate among
urological cancers; renal carcinomas have many histological cell types and may be heterogenous with
different biology and therapeutic sensitivities [32–34]. In many cases, published data on the incidence
and mortality of urologic cancers is hard to interpret and compare, as disease classifications and
ever-changing and endpoints used in the respective studies generally do not match [32–34].
Table 2. Different types of male and female urological cancers.
Bladder cancer
Renal (kidney) cancer
Testicular cancer
Prostate cancer
Penile cancer
Urethral cancer
Padureanu et al. described a case of a 20-year-old patient, with complaints of hematuria,
dysuria, and colicky pain, which were later found to be the caused by the urological manifestation
of tuberous sclerosis complex (TSC) [35]. Pan et al. assessed the incidence of bladder cancer
in patients with Type 2 diabetes mellitus (T2DM) in a study population of 31,932 T2DM patients,
compared to the control group of 63,864 patients without diabetes: overall, they have found that
T2DM patients do not have a higher risk of developing bladder cancer [36]. Lee et al. studied
the potential anticancer properties of epigallocatechin gallate (EGCG) on a human urinary bladder
transitional cell carcinoma (TCC) cell line; during the analyses, the expression profiles of mRNAs and
microRNAs were analyzed using next-generation sequencing (NGS) and bioinformatics. Overall,
they identified several differentially expressed genes in response to EGCG treatment, notably those
involved in redox-metabolism, inflammatory response, and nicotinamide adenine dinucleotide (NAD)
biogenesis, which may all have important roles in the persistence of malignant cells [37]. Anglickis et al.
compared the efficacy of microwave thermal ablation (MWT) with open partial nephrectomy (OPN)
in the treatment of small renal tumors patients over 70 years old in the period between January 2012 and
January 2019 in Lithuania. In their report, they found that MWT was the more advantageous method
overall (assessed by the pain level reported by the patients after surgery (p = 0.008), hospitalization,
and operation time (p < 0.001)), while there were no differences seen in oncological data and the blood
loss-estimated glomerular filtration rate [38]. Augliené et al. assessed the survival rate of renal grafts
from cadavers in a tertiary-care center in Lithuania over a 7-year period (2007–2013), which included
the data analysis of n = 186 renal transplant patients. The authors have found nine independent
variables associated with worse renal transplant function assessed one year post transplantation,
including arteriolar acute graft rejection, an episode of a UTI, advanced age of the donor, advanced
age of the recipient, cerebrovascular disease-caused death in the donor, expanded criteria, female
gender donors, and hyalinosis [39]. Mansour et al. compared the microbiota composition of cancerous
tissues and urine samples collected from bladder carcinoma patients via 16S rRNA gene sequencing,
in an attempt to improve screening and monitoring methods of the disease. In their study, the duplicate
analysis of the tissues was reproducible, and the results were independent from the tissue collection
site. Compared to the urine microbiota, Akkermansia, Bacteroides, Clostridium sensu stricto, Enterobacter,
and Klebsiella were found to be more abundant in tissue samples [40]. Stuopelytė et al. aimed to
assess the miRNA expression-profile in the urine and the prostate tissue of prostate cancer patients,
with the aim of using it as a non-invasive diagnostic modality. In their study, expression profiles
were determined in 13 prostate cancer tissues using microassay analysis, and the highly expressed
human miRNAs were selected for additional analysis by PCR. Based on their findings, upregulation
of miR-95 was associated with an aggressive clinical presentation of prostate cancer; in addition,
increased levels of miR-19a, miR-19b, and miR-21 were also detected in both prostate cancer tissue and
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the urine of the affected patients. Their results indicated that the measurement of the levels of specific
miRNAs may lead to improved detection of prostate cancer [41].
The publication of various microbiological and clinical studies in urology from different
geographical regions has important ramifications from the standpoint of epidemiology: on the one
hand, reported data may influence the development of therapeutic guidelines for UTIs (empiric
antibiotic-therapy) and malignancies (including classical cytotoxic drug protocols and next-generation
anticancer therapies), both locally and internationally; on the other hand, the relevant stakeholders
and government representatives often base their decisions on published evidence [1,5,9,33]. Therefore,
novel studies in the field of urology are strongly encouraged to maintain and improve the high
standard of patient-care internationally and to ensure continuous information supply for international
datasets on the causative agents of UTIs and cancer registries. The registries allow for the accumulation
of large datasets; the secondary analysis of these datasets may provide important insights for the future
of patient care in this field [1,5,9,33].
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